ATE405279T1 - Immobilisierung und stabilisierung von viren - Google Patents

Immobilisierung und stabilisierung von viren

Info

Publication number
ATE405279T1
ATE405279T1 AT03725350T AT03725350T ATE405279T1 AT E405279 T1 ATE405279 T1 AT E405279T1 AT 03725350 T AT03725350 T AT 03725350T AT 03725350 T AT03725350 T AT 03725350T AT E405279 T1 ATE405279 T1 AT E405279T1
Authority
AT
Austria
Prior art keywords
immobilization
viruses
stabilization
immobilized
antibiotic
Prior art date
Application number
AT03725350T
Other languages
English (en)
Inventor
Hugh Scott
Michael Mattey
Original Assignee
Univ Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Strathclyde filed Critical Univ Strathclyde
Application granted granted Critical
Publication of ATE405279T1 publication Critical patent/ATE405279T1/de

Links

Classifications

    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
    • D06M16/003—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic with enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10151—Methods of production or purification of viral material
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M2400/00—Specific information on the treatment or the process itself not provided in D06M23/00-D06M23/18
    • D06M2400/01—Creating covalent bondings between the treating agent and the fibre

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Textile Engineering (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
AT03725350T 2002-04-27 2003-04-28 Immobilisierung und stabilisierung von viren ATE405279T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0209680.8A GB0209680D0 (en) 2002-04-27 2002-04-27 Immobilisation and stabilisation of bacteriophage

Publications (1)

Publication Number Publication Date
ATE405279T1 true ATE405279T1 (de) 2008-09-15

Family

ID=9935641

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725350T ATE405279T1 (de) 2002-04-27 2003-04-28 Immobilisierung und stabilisierung von viren

Country Status (9)

Country Link
US (2) US7482115B2 (de)
EP (2) EP1982723A1 (de)
JP (2) JP5486144B2 (de)
AT (1) ATE405279T1 (de)
AU (1) AU2003227890A1 (de)
DE (1) DE60323077D1 (de)
ES (1) ES2310658T3 (de)
GB (1) GB0209680D0 (de)
WO (1) WO2003093462A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109853A1 (en) 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
EP1599727B1 (de) * 2003-03-04 2008-05-14 Nmi Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen Verfahren zur herstellung eines trägers mit immobilisierten viren und verwendung eines derartigen trägers
WO2005026269A1 (en) * 2003-09-04 2005-03-24 Mcdaniel C Steven Microorganism coating components, coatings, and coated surfaces
MX2007005279A (es) * 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Composiciones de bacteriofagos.
EP1812025B1 (de) * 2004-11-02 2012-09-05 Chr. Hansen A/S Stabilisierte bakteriophagen-formulierungen
CA2593992A1 (en) * 2004-12-06 2006-06-15 Rodney M. Donlan Inhibition of biofilm formation using bacteriophage
JPWO2006082958A1 (ja) * 2005-02-07 2008-06-26 タカラバイオ株式会社 レトロウイルスの保存方法
GB0526176D0 (en) 2005-12-22 2006-02-01 Blaze Venture Technologies Ltd Particle binding
US9364215B2 (en) * 2006-01-26 2016-06-14 Covidien Lp Medical device package
US20090209031A1 (en) * 2006-01-26 2009-08-20 Tyco Healthcare Group Lp Medical device package
CA2604433A1 (en) * 2006-10-06 2008-04-06 Tyco Healthcare Group Lp Medical device package including self-puncturable port
FR2928656B1 (fr) * 2008-03-14 2011-08-26 Biomerieux Sa Procede de detection en temps reel de microorganismes dans un milieu de culture liquide par agglutination.
US20120041287A1 (en) 2008-12-04 2012-02-16 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including implantable devices with anti-microbial properties
US8388904B1 (en) 2008-12-22 2013-03-05 Reactive Surfaces, Ltd., Llp Equipment decontamination system and method
GB201110647D0 (en) 2011-06-23 2011-08-10 Fixed Phage Ltd Delivery of viral agents
WO2013048604A2 (en) * 2011-06-28 2013-04-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Controlled covalent attachment of bioactive bacteriophage for regulating biofilm development
GB201217097D0 (en) * 2012-09-25 2012-11-07 Fixed Phage Ltd Treatment of bacterial infection
US20160010077A1 (en) * 2013-02-28 2016-01-14 The University Of Southern Mississippi Covalent Attachment of Bacteriophages (Phages) to Polymeric Surfaces
GB201402139D0 (en) * 2014-02-07 2014-03-26 Fixed Phage Ltd Treatment of topical and systemic bacterial infections
GB2540688B (en) 2014-03-31 2021-04-21 Kimberly Clark Co Self-regenerating antimicrobial composition and method of use
DK3285787T3 (da) * 2015-04-20 2020-05-18 Fixed Phage Ltd Behandling af bakterieinfektioner i akvakultur
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
EP3461345A1 (de) * 2017-09-28 2019-04-03 Fixed Phage Limited Antibakterielle verpackung
EP3616730A1 (de) 2018-08-28 2020-03-04 UPM-Kymmene Corporation Zusammensetzung oder matrix zur lagerung von bakteriophagen umfassend nanofibrillarzellulose
US20220008888A1 (en) 2018-11-22 2022-01-13 Fixed Phage Limited Production of immobilised bacteriophage
US20220183324A1 (en) 2019-04-10 2022-06-16 Fixed Phage Limited Continuous treatment with plasma
GB201907796D0 (en) * 2019-05-31 2019-07-17 Aquila Bioscience Device and method for decontamination/disinfection
KR20220164757A (ko) 2020-04-08 2022-12-13 엘리고 바이오사이언스 마이크로바이옴-연관 질환 또는 장애의 예방, 치료 또는 치유를 위한 마이크로바이옴의 유전자 요법에 의한 미생물총 기능의 조절
US11617773B2 (en) 2020-04-08 2023-04-04 Eligo Bioscience Elimination of colonic bacterial driving lethal inflammatory cardiomyopathy
DE21179356T1 (de) 2020-06-12 2022-02-17 Eligo Bioscience Spezifische entkolonisierung von antibiotikaresistenten bakterien für prophylaktische zwecke
WO2022003209A1 (en) 2020-07-03 2022-01-06 Eligo Bioscience Method of containment of nucleic acid vectors introduced in a microbiome population
WO2022144382A1 (en) 2020-12-30 2022-07-07 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
CN113755480B (zh) * 2021-03-19 2023-12-05 威海纽普生物技术有限公司 病毒固相感染体外培养细胞的方法
AU2022272135A1 (en) 2021-05-12 2024-01-04 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
EP4136974A1 (de) 2021-08-20 2023-02-22 Fixed Phage Limited Plasmabehandlungsverfahren und entsprechendes gerät
JP2025505317A (ja) 2022-02-08 2025-02-21 オックスフォード シルク ファージ テクノロジーズ リミテッド バクテリオファージを含有するフィラメントから物品を製造する方法および装置
WO2023152549A1 (en) * 2022-02-11 2023-08-17 Phagelab Chile Spa Compositions for the treatment of e. coli and salmonella
WO2024013468A1 (en) 2022-07-11 2024-01-18 University Court Of The University Of St Andrews Functionalised metal-organic framework
GB202210434D0 (en) 2022-07-15 2022-08-31 Carus Animal Health Ltd Agricultural compositions and methods
GB202210435D0 (en) * 2022-07-15 2022-08-31 Carus Animal Health Ltd Agricultural compositions and methods
GB2631119A (en) 2023-06-20 2024-12-25 Innovia Films Ltd Anti-bacterial article
GB202400580D0 (en) 2024-01-16 2024-02-28 Carus Animal Health Ltd Therapeutic compositions and methods
DE102024113842A1 (de) * 2024-05-16 2025-11-20 bifa Umweltinstitut GmbH Verfahren zur Verringerung der bakteriellen Last auf bzw. in einer Klimaanlage

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
JPH0271152A (ja) * 1988-09-07 1990-03-09 Terumo Corp 固相免疫測定用成形品の製造法
GB8918983D0 (en) * 1989-08-21 1989-10-04 Unilever Plc Composition for hygiene purposes
US5229172A (en) * 1993-01-19 1993-07-20 Medtronic, Inc. Modification of polymeric surface by graft polymerization
AU679228B2 (en) * 1993-04-27 1997-06-26 Symbiotech, Inc. Method of detecting compounds utilizing chemically modified lambdoid bacteriophage
AU699322B2 (en) * 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US5695777A (en) * 1994-05-10 1997-12-09 Medtronic, Inc. Absorptive wound dressing for wound healing promotion
DE19828596A1 (de) * 1997-06-26 1999-02-11 A Daniela Dr Nodar Wirksames Arzneimittel gegen bakterielle Erkrankungen und Herstellung desselben
GB9809414D0 (en) * 1998-05-02 1998-07-01 Scottish Crop Research Inst Method
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
GB9908195D0 (en) * 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
EP1180937A4 (de) * 1999-05-13 2004-08-04 Exponential Biotherapies Inc Für die rettung von mit vancomycin-resistentem enterococcus faecium infizierten patenten verwendbarer bakteriophagenstamm
AU781090B2 (en) * 1999-07-30 2005-05-05 Biomerieux S.A. Detection and identification of bacterial strains
US20020001590A1 (en) * 2000-04-20 2002-01-03 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
WO2002007742A2 (en) * 2000-07-25 2002-01-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage having multiple host range

Also Published As

Publication number Publication date
US7482115B2 (en) 2009-01-27
JP5486144B2 (ja) 2014-05-07
ES2310658T3 (es) 2009-01-16
EP1982723A1 (de) 2008-10-22
AU2003227890A1 (en) 2003-11-17
JP5504302B2 (ja) 2014-05-28
JP2012211135A (ja) 2012-11-01
EP1496919A2 (de) 2005-01-19
AU2003227890A8 (en) 2003-11-17
WO2003093462A2 (en) 2003-11-13
JP2005523943A (ja) 2005-08-11
WO2003093462A3 (en) 2004-02-12
US20050220770A1 (en) 2005-10-06
DE60323077D1 (de) 2008-10-02
GB0209680D0 (en) 2002-06-05
EP1496919B1 (de) 2008-08-20
US20090214617A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
DE60323077D1 (de) Immobilisierung und stabilisierung von viren
DE60143672D1 (de) Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
TR200201484T2 (tr) Çeşitli hastalıkların koruyucu ve iyileştirici tedavisi için bakteriyel fajlar ile ilişkili lisleme enzimlerinin kullanımı
GEP20084545B (en) Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
EP1377314A4 (de) Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
ATE544466T1 (de) Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
EA200700243A1 (ru) Способы лечения гепатита с
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
TW200633995A (en) Andrographolide derivatives to treat viral infections
CL2004000261A1 (es) Procedimiento para la eliminacion de virus en soluciones de fibrinogeno de aplicacion terapeutica.
DE602006018746D1 (de) Ply-gbs-lysinmutanten
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
TR200101841T2 (tr) Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
EP2021023A4 (de) Myxom-virusmutanten zur krebsbehandlung
DE60128407D1 (de) Verwendung einer pharmazeutischen zusammensetzung enthaltend zwei quaternäre ammoniumverbindungen und eine organometal-verbindung zur behandlung von viralen und fungalen infekten und krankheiten
ATE442155T1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
WO2004024099A3 (en) Methods and devices for treating severe peripheral bacterial infections
RU2002135207A (ru) Средство "арголит" для лечения инфицированных ран
EA200870263A1 (ru) Внутривенный способ лечения вирусной инфекции
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties